Broggi E, May A, Giretti G, Tabchouri N, Lorphelin H, Brichart N, Bruyère F
Urology Department, CHRU de Tours, Tours, France.
Urol Int. 2014;93(2):229-36. doi: 10.1159/000356991. Epub 2014 Mar 12.
Photoselective vaporization of the prostate (PVP) is becoming a surgical treatment alternative of transurethral resection of the prostate for male lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). We evaluated the outcome and postoperative complications of PVP performed by 80-W KTP and 120-W HPS GreenLight lasers (AMS®) over a 4-year period.
This is a prospective monocentric study that included all patients who underwent PVP. They had routine follow-up at 1 month, 3 months, 6 months and every year until the fourth postoperative year. Listed data were maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), post-void residual (PVR) volume, prostate-specific antigen (PSA) and prostate volume. We collected the postoperative complications.
From September 2005 to May 2008, 77 patients out of a 409 patients cohort underwent surgery and were followed during 4 years. At 4 years mean Qmax increase was 82.5%; mean IPSS, PVR volume, PSA and prostate volume decreases were 79.1, 69.8, 43.8 and 22.9%, respectively. The main side effects observed were storage LUTS. A urinary catheter was replaced after a first withdrawal failure in 10 patients (15.6%) after surgery.
PVP showed a sustainable efficacy and an appealing tolerance profile during a 4-year period in patients with LUTS secondary to BPO.
对于因良性前列腺梗阻（BPO）继发男性下尿路症状（LUTS）的患者，前列腺光选择性汽化术（PVP）正成为经尿道前列腺切除术的一种手术治疗替代方案。我们评估了80瓦KTP激光和120瓦HPS绿光激光（AMS®）在4年期间实施PVP的疗效及术后并发症。
这是一项前瞻性单中心研究，纳入了所有接受PVP的患者。他们在术后1个月、3个月、6个月以及每年进行常规随访，直至术后第4年。记录的数据包括最大尿流率（Qmax）、国际前列腺症状评分（IPSS）、残余尿量（PVR）、前列腺特异性抗原（PSA）以及前列腺体积。我们收集了术后并发症情况。
从2005年9月至2008年5月，409例患者队列中有77例接受了手术，并进行了4年的随访。4年时，平均Qmax增加了82.5%；平均IPSS、PVR体积、PSA以及前列腺体积分别下降了79.1%、69.8%、43.8%以及22.9%。观察到的主要副作用是储尿期LUTS。术后有10例患者（15.6%）在首次拔导尿管失败后更换了导尿管。
对于因BPO继发LUTS的患者，PVP在4年期间显示出持续的疗效和良好的耐受性。
